Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wormald

Showing results (51-60 of 261) with videos related to

Pageof 27
Sort By:
The Cochrane Database of Systematic Reviews|November 1, 2001
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The Cochrane Database of Systematic Reviews|October 20, 2005
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The Cochrane Database of Systematic Reviews|July 20, 2007
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The British Journal of Ophthalmology|August 26, 1998
Impaired motion sensitivity as a predictor of subsequent field loss in glaucoma suspects: the Roscommon Glaucoma StudyJ Wu, M Coffey, A Reidy, et al.
Lancet (London, England)|September 5, 2006
What's in a name? New glaucoma drugsA Spratt, L Ogunbowale, R Wormald, et al.
The Cochrane Database of Systematic Reviews|October 19, 2007
Laser trabeculoplasty for open angle glaucomaC Rolim de Moura, A Paranhos, R Wormald
Lancet (London, England)|May 20, 1989
Glaucoma and raceD Poinoosawmy, S Nagasubramanian, R Wormald, et al.
The British Journal of Ophthalmology|April 16, 1998
BD8 certification of visually impaired peopleC Bunce, J Evans, S Fraser, et al.
Eye (London, England)|July 12, 2003
Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving targetB Foot, R Foy, U Chakravarthy, et al.
Trends in Biotechnology|September 29, 2004
Sugar-mediated ligand-receptor interactions in the immune systemPauline M Rudd, Mark R Wormald, Raymond A Dwek
Pageof 27

Showing results (51-60 of 261) with videos related to

Sort By:
Pageof 27
The Cochrane Database of Systematic Reviews|November 1, 2001
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The Cochrane Database of Systematic Reviews|October 20, 2005
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The Cochrane Database of Systematic Reviews|July 20, 2007
Photodynamic therapy for neovascular age-related macular degenerationR Wormald, J Evans, L Smeeth, et al.
The British Journal of Ophthalmology|August 26, 1998
Impaired motion sensitivity as a predictor of subsequent field loss in glaucoma suspects: the Roscommon Glaucoma StudyJ Wu, M Coffey, A Reidy, et al.
Lancet (London, England)|September 5, 2006
What's in a name? New glaucoma drugsA Spratt, L Ogunbowale, R Wormald, et al.
The Cochrane Database of Systematic Reviews|October 19, 2007
Laser trabeculoplasty for open angle glaucomaC Rolim de Moura, A Paranhos, R Wormald
Lancet (London, England)|May 20, 1989
Glaucoma and raceD Poinoosawmy, S Nagasubramanian, R Wormald, et al.
The British Journal of Ophthalmology|April 16, 1998
BD8 certification of visually impaired peopleC Bunce, J Evans, S Fraser, et al.
Eye (London, England)|July 12, 2003
Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving targetB Foot, R Foy, U Chakravarthy, et al.
Trends in Biotechnology|September 29, 2004
Sugar-mediated ligand-receptor interactions in the immune systemPauline M Rudd, Mark R Wormald, Raymond A Dwek
Pageof 27